Abnormal serum lipoprotein levels as a risk factor for the development of human lenticular opacities

Cardiovascular Journal of South Africa

Volumn 14, Issue 2, 2003, Pages 60-64

  Meyer, D ^a   Parkin, D ^a   Maritz, F J ^a   Liebenberg, P H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CALCULATION; CATARACT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYDRIASIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SLIT LAMP;

EID: 0038451407     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. World Health Organization. Management of Cataracts in Primary Health Care Services. Geneva: WHO 1990.
2. Epstein FH. Cardiovascular disease epidemiology; a journey from the past into the future. Circulation 1996; 93: 1755-1764.
3. Hyman L. Epidemiology of eye disease in the elderly. Eye 1987; 1: 330-341.
4. Anderson JW, Hanna TJ. Impact of nondigestible carbohydrates on serum lipoproteins and risk for cardiovascular, disease. J Nutr 1999; 129(7) Suppl): 14575-14665.
5. Meyer D, Maritz FJ, Liebenberg PH, Parkin DP, Burgess LJ. Cortical opacities in the young patient - an indication for a lipogram? S Afr Med J 2001; 91: 520-524.
6. Merck Manual. 17th edn, 2000.
7. Assman G, Schulte H. In: Assmann G, ed. Lipid Metabolism Disorders and Coronary Heart Disease. 2nd edn. Munich: MMV-Medizin-Verl., 1993: 28.
8. Goodrich ME, Cumming RG, Mitchell P, Koutts J, Burnett L. Plasma fibrinogen and other cardiovascular disease risk factors and cataract. Ophthalmic Epidemiol 1999; 6(4): 279-290.
9. Jacob RA, Burri BJ. Oxidative damage and defense. Am J Clin Nutr 1996; 63(6): 985S-990S.
10. Lerman S. Biophysical aspects of corneal and lenticular transparency. Curr Eye Res 1984; 3: 3-14.
11. Spector A. Oxidative stress-induced cataract: mechanism of action. FASEB J 1995; 9(12): 1173-1182.
12. Goodrich ME, Cumming RG, Mitchell P. Koutts J, Burnett L. Plasma fibrinogen and other cardiovascular disease risk factors and cataract. Ophthalmic Epidemiol 1999; 6(4): 279-290.
13. Varma SD, Ets T, Richards RD. Protection against superoxide radicals in rat lens, Ophthalmic Res 1977; 9: 421-431.
14. Varma SD, Kumar S, Richards RD. Light-induced damage to ocular lens cation pump: prevention by vitamin C. Proc Nat Acad Sci USA 1979; 76: 3504-3506.
15. Varma SD. Superoxide and lens of the eye: a new theory of cataractogenesis. Int J Quantum Chem 1981; 20: 479-484.
16. Kinscy VE, Frohman CE. Studies on the crystalline lens. IV. Distribution of cytochrome, total riboflavin, lactate, and pyruvate and their metabolic significance. Arch Ophthalmol 1951; 46: 536-541.
17. Van Heyningen R. Fluorescent derivatives of 3-hydroxy-L-kynurenine in lens of man, the baboon and the grey squirrel. Biochem J 1971; 23: 300-311.
18. Masey V, Strickland SG, Mayhew LG, et al. The production of superoxide anion radicals in the reaction of reduced flavins and flavoproteins with molecular oxygen. Biochem Biophys Res Com 1969; 36: 891-897.
19. 2 and human cataract. Rep Eye Res 1981; 33: 673-681.
20. Bhuyan KC, Bbuyan DK. Molecular mechanism of cataractogenesis: Toxic metabolites of oxygen as initiators of lipid peroxidation and cataract. Curr Eye Res 1984; 3: 67-81.
21. Ohrloff C, Hockwin O. Superoxide dismutase (SOD) in normal and cataractous human lenses. Graefe's Arch Gun Exp Ophthalmol 1984; 222: 79-81.
22. Kamei A. Glutathione levels of the human crystalline lens in aging and its antioxidant effect against the oxidation of lens proteins. Dial Pharm Ridl 1993; 16: 870-875.
23. Smith LL. Review of progress in sterol 1987-1995. Lipids 1996; 31: 453-587.
24. Garner MH, Roy D, Rosenfeld D, Garner WH and Spector A. Biochemical evidence for membrane disintegration in human cataract. Proc Nat Acad Sci USA 1981; 78: 1892-1895.
25. Girao H, Mota MC, Ramalho J, Pereira P. Cholesterol oxides accumulate in human cataracts. Exp Eye Res 1998; 66(5): 645-652.
26. Smith LL. Review of progress in sterol 1987-1995. Lipids 1996; 31: 453-587.
27. Haliwell B. Albumin: an important extracellular antioxidant. Biochem Pharmacol 1988; 37: 569-571.
28. Girao H, Mota C, Pereira P. Cholesterol may act as an antioxidant in lens membranes. Curr Eye Res 1999; 18(6): 448-454.
29. Goodrich ME, Cumming RG, Mitchell P, Koutts J, Burnett L. Plasma fibrinogen and other cardiovascular disease risk factors and cataract. Ophthalmic Epidemiol 1999; 6(4): 279-290.
30. Farinaro E, Lewis B, Assman G, Stein Y, Galton D, Deckelbaum J, et al. In: Assmann G, ed. Lipid Metabolism Disorders and Coronary Heart Disease. 2nd edn. Munich: MMV-Medizin-Verl., 1993: 69-139.